PMID: 11918561Mar 29, 2002Paper

CD34+/CD90+ cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation

British Journal of Haematology
Toshiya SumikumaMasao Nakagawa

Abstract

This study aimed to identify which graft product subset of cells might be the most predictive of late haematopoietic recovery (three to 12 months) following autologous peripheral blood stem cell transplantation (PBSCT). The relationships between the numbers of reinfused CD34+ cells and their immature subsets such as CD34+/CD90+, CD34+/AC133+, CD34+/CD38- and CD34+/HLA-DR- cells, and haemoglobin, white blood cell (WBC) and platelet counts at 3, 6, 9 and 12 months after PBSCT, were studied in 25 patients with haematological and solid malignancies. The total CD34+ cell number, as well as CD34+/CD90+ and CD34+/AC133+ cell numbers, correlated with platelet counts at 3, 6, 9 and 12 months after PBSCT, but the CD34+/CD90+ cells infused best predicted platelet recovery during the first 12 months after PBSCT (P < 0.0238 at any time-point). The CD34+/AC133+ cell dose also correlated with WBC counts at 3 months post PBSCT. In addition, all patients receiving more than 80 x 10(4) CD34+/CD90+ cells/kg showed platelet counts greater than 100 x 10(9)/l at all points after PBSCT, suggesting that this value of the CD34+/CD90+ cells infused was a threshold dose for durable haematopoietic engraftment after PBSCT.

References

Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·C M BaumB Peault
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M W DercksenC E van der Schoot
May 1, 1993·The Journal of Experimental Medicine·W CraigP M Lansdorp
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A L PecoraJ A Brochstein
Feb 27, 2001·Bone Marrow Transplantation·P R DugganD A Stewart

❮ Previous
Next ❯

Citations

Apr 3, 2004·British Journal of Haematology·Francesco BuccisanoValter Gattei
May 23, 2003·American Journal of Clinical Pathology·Anthony ChangSteven J Kussick
Apr 7, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shifra AshSmadar Avigad
Feb 11, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kieuhoa T VoSteven G Dubois
Nov 13, 2004·Stem Cells·Tai-Wei David LeongDietmar Werner Hutmacher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.